Head-to-head for women
Hers vs Zealthy
Hers and Zealthy both offer GLP-1 telehealth to women, but they make different trade-offs on PCOS and hormonal suitability, clinical oversight, price and access. Here they are side-by-side on the Metabolic-Fit Score — our women's-health rubric.
Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Prices and terms come from the company's own published pages. This is background reading, not medical advice.
Hers
Higher scoreMetabolic-Fit 63/100 · Grade C
Metabolic-Fit / 100
Best for: Mothers who want a familiar, app-driven consumer brand and are comfortable budgeting for a separate membership fee on top of the posted medication price.
Visit HersZealthy
Metabolic-Fit 33/100 · Grade C
Metabolic-Fit / 100
Best for: Nothing, while the federal case is open. It stays on the board for transparency, not as a suggestion.
Visit ZealthyThe verdict for women
Hers edges out Zealthy on the Metabolic-Fit Score, 63 to 33 (C vs C). Mothers who want a familiar, app-driven consumer brand and are comfortable budgeting for a separate membership fee on top of the posted medication price.
Zealthy is still a genuine option — fDA warning letter #716501 (Sept. 2025), which names Zealthy's website, and in April 2026 the FTC and DOJ moved to seize the company and freeze its assets. Read both before anything else here. Semaglutide: Medication from $151/mo; total program cost requires confirmation; tirzepatide: Current public tirzepatide cash total not itemized. The medication sticker does not establish total program cost, and no current tirzepatide cash total is itemized publicly. Weigh the six women's-health factors below against your own priorities.
Side-by-side on the six factors
Both providers scored on the same women's-health rubric — the higher side on each factor is marked. See the methodology.
Price, access & features
Price highlights compare average monthly budgets, using 52 weeks ÷ 12 months for weekly cycles. Quoted charges retain their billing units; unknown periods and fee-only or prepaid quotes do not compete.
| Detail | Hers | Zealthy |
|---|---|---|
| Metabolic-Fit Score | 63/100 · C | 33/100 · C |
| Overall rank | #33 | #308 |
| Semaglutide | $149/mo Wegovy Pill + $149/mo membership (~$298/mo all-in) | Total price unconfirmed; medication advertised from $151/mo |
| Tirzepatide | $299/mo Zepbound + $149/mo membership (~$448/mo all-in) | Current public tirzepatide cash total not itemized |
| Coverage | Not available in all 50 states; no complete list published | Most states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
The decision beyond the score
Hers publishes a combined starting total; Zealthy leaves a gap
Hers lists brand-name medication with a required $149 ordinary monthly membership, discounted to $39 for the first month. Starting drug prices give approximate ongoing totals of $298 for a Wegovy pill, $348 for a Wegovy pen and $448 for Zepbound. Those are dose-sensitive starting totals, not guarantees for every refill. Zealthy's semaglutide advertisement begins at $151 for medication, while the complete program charge and working-dose conditions are not fully itemized. The $151 should therefore not be ranked against Hers' combined amounts as though both numbers paid for the same complete service.
Zealthy's current public tirzepatide cash total is also not established. An insured brand copay advertisement, where offered, depends on eligibility and coverage and does not supply that missing cash quote. Ask for the prescribed finished product, the care charge, the medication charge and the payment schedule before committing. Hers' current menu provides FDA-approved brand products; Zealthy's compounded route is a different product category. Comparing ingredient names without identifying the formulation can obscure a more important clinical distinction than any apparent saving. A prescriber should explain why the particular product is being considered.
The legal histories should be distinguished rather than combined
Hers' September 2025 FDA warning letter concerned its earlier compounded-semaglutide business, preceding the current brand-name menu. Zealthy received FDA warning letter #716501, issued to FitRX, LLC dba Zealthy on September 9, 2025 and naming getzealthy.com. These are separate letters to separate businesses, not evidence that the current offerings have identical regulatory status. Disclosing both histories helps a reader evaluate the companies without suggesting that a historical letter predicts an individual patient's outcome or that an approved brand medicine becomes a compounded product because the seller previously offered one.
Zealthy also faces April 2026 FTC and DOJ allegations involving billing disclosures, cancellation, reviews and clinicians' identifiers. Allegations are not findings of liability, and this comparison does not establish the case's present procedural status. They are nevertheless material reasons to seek written billing and cancellation terms. Neither company's presentation establishes dedicated maternal care, and both require specific geographic eligibility confirmation. Hers offers clearer starting brand totals in this pair; Zealthy's unresolved complete price and documented legal concerns require answers before a claimed budget advantage can be assessed. Choose only after the clinical product and continuing financial obligations are explicit.
Based on the public terms documented in the Hers review and Zealthy review. Each review details the prices and terms. Confirm current terms before paying.
Metabolic-Fit / 100
Hers
Metabolic-Fit 63/100 · Grade C
What we like
- Explicit women-focused positioning and a brand many mothers already trust
- Now selling FDA-approved brand-name medication (Wegovy, Zepbound) rather than compounded semaglutide
- An app with oral and injectable brand-name options; availability varies by state.
The caveats
- Carries an FDA warning letter dated September 2025 over the prior compounded-semaglutide business, before this pivot to brand-name product
- The posted 'from $149/mo' price is medication only — a required $149/mo membership (billed separately, $39 the first month) roughly doubles the real ongoing cost
- A general weight program, not a clinician-led metabolic service with postpartum or PCOS specialization
Metabolic-Fit / 100
Zealthy
Metabolic-Fit 33/100 · Grade C
What we like
- Semaglutide: Medication from $151/mo; total program cost requires confirmation; tirzepatide: Current public tirzepatide cash total not itemized.
The caveats
- No dedicated postpartum, breastfeeding, or PCOS framing
- April 2026: the FTC and DOJ asked a federal court to place Zealthy in receivership and freeze its assets, alleging deceptive disclosures, obstructive cancellation and review manipulation
- The same complaint alleges misuse of clinicians' NPI numbers to issue prescriptions without their knowledge or consent — the government's words are that Zealthy is "actively deceiving telehealth patients, endangering their safety, and raiding their bank accounts". These are allegations, not findings; the case is ongoing
Some outbound links earn MomMetabolic a referral fee at no added cost to you, walled off from the Metabolic-Fit Score. Pricing, states and verification reflect each provider's public disclosures at last review; the Metabolic-Fit Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.
More head-to-heads
Comparisons close to Hers vs Zealthy.
- Form Health vs Hers
- CoreAge Rx vs Calibrate
- CoreAge Rx vs Sesame
- CoreAge Rx vs Wellorithm
- CoreAge Rx vs Ro
- CoreAge Rx vs Form Health
Or browse the full comparison hub.